Focus Partners Wealth Has $18.18 Million Position in Zoetis Inc. (NYSE:ZTS)

Focus Partners Wealth cut its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 68.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 108,970 shares of the company's stock after selling 240,281 shares during the quarter. Focus Partners Wealth's holdings in Zoetis were worth $18,182,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in ZTS. Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. boosted its position in Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after buying an additional 166 shares during the last quarter. Navigoe LLC acquired a new stake in Zoetis in the fourth quarter worth about $30,000. Murphy & Mullick Capital Management Corp acquired a new position in Zoetis in the fourth quarter valued at approximately $44,000. Finally, Asset Planning Inc bought a new position in shares of Zoetis in the 4th quarter worth $58,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

ZTS traded up $5.34 on Thursday, reaching $160.26. The company had a trading volume of 3,536,194 shares, compared to its average volume of 2,511,454. The stock has a market cap of $71.35 billion, a P/E ratio of 29.30, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The company's fifty day moving average is $156.72 and its 200 day moving average is $165.71.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm's quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.38 earnings per share. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on ZTS shares. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. UBS Group decreased their price objective on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Piper Sandler increased their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday. Finally, StockNews.com raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $212.75.

Insider Buying and Selling at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the firm's stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now directly owns 11,245 shares of the company's stock, valued at $1,868,244.30. This trade represents a 9.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at approximately $2,682,770. This represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.